Pay in 4 interest-free payments of $5.18 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Selective DNA methylation of BDNF promoter in bipolar disorder: differences among patients with BDI and BDII
Gomes, C
If BPC-157 was purchased today, the patent would likely expire in 2033 before the phase 1-2-3 trials would be completed, at which point all the generic manufacturers would be able to push the product on the back of all the hard work a pharmaceutical company can do (Im not sure if FDA approval would push the expiration of the patent back, but even then it would not be so financial lucrative)
AOD-9604 originated from research at Monash University in the 1990s seeking to isolate the lipolytic domain of human growth hormone from its growth-promoting and metabolic-side-effect domains
US$ 23.58
US$ 26.05
US$ 24.00
